Cardiology Associates Research
Welcome,         Profile    Billing    Logout  
 16 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bertolet, Barry
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Recruiting
3
14000
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
03/29
03/29
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Completed
2
194
Europe, Japan, US, RoW
Experimental drug, Placebo
Novartis Pharmaceuticals
Resistant Hypertension
07/24
08/24
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
FORWARD PAD, NCT05858905: IDE Study With the Shockwave Mini S IVL Catheter

Active, not recruiting
N/A
75
US
Intravascular Lithotripsy
Shockwave Medical, Inc.
Peripheral Arterial Disease
04/24
04/25
ALLEVIATE-HF, NCT04452149: Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Active, not recruiting
N/A
826
US
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention
Medtronic Cardiac Rhythm and Heart Failure
Heart Failure NYHA Class II, Heart Failure NYHA Class III
05/25
05/25
MAGICAL ISR, NCT05908331: MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Recruiting
N/A
492
US
Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA)
Concept Medical Inc., Cardiovascular Research Foundation, New York
In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
09/25
02/28
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
ELEGANCE, NCT04674969: Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Recruiting
N/A
5000
Europe, Canada, US, RoW
Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Boston Scientific Corporation
Peripheral Vascular Diseases
01/28
01/28
Krucoff, Mitchell W
NCT02843633: LEADERS FREE II: BioFreedom™ Pivotal Study

Active, not recruiting
N/A
1203
Europe, Canada, US
BioFreedom™ Drug Coated Coronary Stent System, Coronary Angioplasty, Antiplatelet Drug
Biosensors Europe SA
Acute Coronary Syndrome, High Bleeding Risk
10/18
03/21
NCT02939976: Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)

Terminated
N/A
428
US
Single Vessel Disease, Multi-vessel Disease, Culprit Vessel Only, Multi-vessel Disease, Complete Revascularization, Medtronic Resolute family of stents, Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology, Terumo Glidesheath Slender, Terumo TR Band Radial Compression Device
David Kong, M.D., Medtronic Vascular, Volcano Corporation, Terumo Medical Corporation
Myocardial Infarction
07/23
07/23
NCT05412927: AngelMed Guardian® System PMA Post Approval Study

Recruiting
N/A
500
US
PMA P150009 AngelMed Guardian® System
Angel Medical Systems
Acute Coronary Syndrome
12/26
12/26
Talton, David
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Eads, Kristin
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Completed
2
194
Europe, Japan, US, RoW
Experimental drug, Placebo
Novartis Pharmaceuticals
Resistant Hypertension
07/24
08/24
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
Gupta, Amit
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
NCT05456425: A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Recruiting
3
600
US, RoW
CBT-001, Vehicle
Cloudbreak Therapeutics, LLC
Pterygium
12/25
12/26
NCT06597968: Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool

Not yet recruiting
N/A
45991
US
AI Based CAD Software (qXR-Ln)
Amit Gupta, MD
Lung Nodule
09/25
09/25
NCT03193528: A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer

Recruiting
N/A
450
Japan, US
Cedars-Sinai Medical Center, Fred Hutchinson Cancer Center, University of Texas, Nara Medical University, University of California, Los Angeles, Nonagen Bioscience Corporation, National Cancer Institute (NCI), University of Rochester, Nara Prefecture Seiwa Medical Center
Bladder Cancer
12/25
12/25
NCT03193541: A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

Recruiting
N/A
900
Japan, US
Cedars-Sinai Medical Center, Nonagen Bioscience Corporation, Nara Medical University, University of California, Los Angeles, University of Rochester, National Cancer Institute (NCI), University of Texas, Southwestern Medical Center at Dallas, VA Long Beach Healthcare System, Nara Prefecture Seiwa Medical Center
Bladder Cancer
12/25
12/25
NCT04564781: Predicting BCG Response

Recruiting
N/A
400
Japan, US
Cedars-Sinai Medical Center, National Cancer Institute (NCI), Nonagen Bioscience Corporation, University of California, San Francisco, Kyoto University, University of California, Los Angeles
Bladder Cancer
04/26
12/26
Adams, Joseph
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
Estess, Murray
No trials found
Blossom, Benjamin
No trials found

Download Options